Stockscreener 앱 받기
32.00
3.51%
1.085
시장 영업 전:
32.10
0.105
+0.33%
Vera Therapeutics Inc 주식(VERA)의 최신 뉴스
Scotiabank Increases the Price Target for Vera Therapeutics by $10 - Insider Monkey
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 - MSN
Clinical-Stage Biotech Vera Therapeutics Joins Elite Goldman Sachs Healthcare Conference Lineup - Stock Titan
Watkins Advises Vera Therapeutics in US$500 Million Credit Facility With Oxford Finance - Latham & Watkins LLP
Vera Therapeutics Atacicept: Promising Step In IgAN, But Crowded Road Ahead (Rating Downgrade) - Seeking Alpha
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans - GlobeNewswire
Equities Analysts Set Expectations for VERA Q2 Earnings - Defense World
Vera Therapeutics (NASDAQ:VERA) Sees Large Volume Increase on Analyst Upgrade - Defense World
Peninsula biotech company eyes half-billion dollars after kidney drug study - The Business Journals
Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 By Stocktwits - Investing.com India
Vera Therapeutics (VERA) Secures $500 Million Credit Facility - GuruFocus
Vera Therapeutics (VERA) Sees Price Target Boost Following Positive Trial Results | VERA Stock News - GuruFocus
Vera Therapeutics Secures $500M Loan Agreement - TipRanks
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 ... - Bluefield Daily Telegraph
Vera Therapeutics Lands Massive $500M Financing Deal as FDA Filing for Kidney Drug Approaches - Stock Titan
Two Sigma Investments LP Sells 7,102 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $65.00 at Scotiabank - Defense World
Vera Therapeutics (NASDAQ:VERA) Given New $85.00 Price Target at HC Wainwright - Defense World
Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday - Yahoo
These 10 Stocks Blew Past Expectations - Insider Monkey
Vera Therapeutics (NASDAQ:VERA) Shares Gap Up After Analyst Upgrade - Defense World
Vera Therapeutics: Primary endpoint was met in ORIGIN Phase 3 trial of atacicept - TipRanks
H.C. Wainwright ups Vera Therapeutics target on ‘home run’ data - TipRanks
Buy Rating for Vera Therapeutics: Promising Potential of Atacicept in IgA Nephropathy Treatment - TipRanks
Arthur He CFA Upgrades Vera Therapeutics on Promising Phase 3 Results for Atacicept in IgAN Treatment - TipRanks
Vera’s Atacicept Sets A New Efficacy Bar With Phase III Results In IgAN - insights.citeline.com
Vera Therapeutics (VERA) Surges 67.49% After Landmark Phase 3 Trial Results - Wealth Daily
Evercore ISI maintains outperform rating on Vera Therapeutics stock By Investing.com - Investing.com South Africa
Scotiabank Maintains Sector Outperform Rating for Vera Therapeutics (VERA) | VERA Stock News - GuruFocus
Vera rises after success in late-stage trial for IgA nephropathy treatment - Seeking Alpha
Wedbush Raises Price Target on Vera Therapeutics to $32 From $26, Maintains Neutral Rating - marketscreener.com
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Vera Therapeutics, Inc. Announces Atacicept Achieves 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy - marketscreener.com
Vera Therapeutics Reports Positive Phase 3 Results for Atacicept in IgA Nephropathy Treatment - geneonline.com
Scotiabank Adjusts Price Target on Vera Therapeutics to $65 From $55, Maintains Outperform Rating - marketscreener.com
Vera Therapeutics Says Trial of Kidney Disease Drug Achieves Primary Endpoint; Shares Jump - marketscreener.com
JPMorgan reiterates Vera Therapeutics stock rating after study data By Investing.com - Investing.com South Africa
TD Cowen maintains buy rating for Vera Therapeutics stock - Investing.com
JPMorgan reiterates Vera Therapeutics stock rating after study data - Investing.com
Transcript : Vera Therapeutics, Inc.Special Call - marketscreener.com
VERA: HC Wainwright & Co. Raises Price Target for Vera Therapeutics | VERA Stock News - GuruFocus
Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data - Benzinga
Vera Therapeutics (VERA) Target Price Boosted Following Promising Study Results | VERA Stock News - GuruFocus
Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction In ORIGIN Phase 3 Trial In Adults With IgA Nephropathy - marketscreener.com
Vera Therapeutics Reports Atacicept Reduces Toxic Protein Levels in IgA Nephropathy Trial - geneonline.com
Vera Therapeutics shares soar on positive Phase 3 trial results - Investing.com Australia
Vera Therapeutics shares soar on positive Phase 3 trial results By Investing.com - Investing.com Canada
VERA's Phase 3 Trial of Atacicept Shows Promising Results in IgA - GuruFocus
Vera Therapeutics Announces Positive Phase 3 Trial Results - TipRanks
Why Vera Therapeutics Is Rising In Pre-market? - Nasdaq
Vera Therapeutics Reports Positive Results from ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy, Meeting Primary Endpoint - Nasdaq
Vera Therapeutics reports positive results from trial of kidney disease drug - statnews.com
Vera Therapeutics Announces Atacicept Achieved 46% - GlobeNewswire
Breakthrough: New Drug Cuts Kidney Disease Protein by 46% in Phase 3 TrialFDA Filing Next - Stock Titan
Ameriprise Financial Inc. Raises Stake in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Millennium Management LLC Trims Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Cantor Fitzgerald maintains $100 target on Vera Therapeutics stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald maintains $100 target on Vera Therapeutics stock - Investing.com Australia
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of “Buy” by Analysts - Defense World
Cantor Fitzgerald maintains Vera Therapeutics at Overweight By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains Vera Therapeutics at Overweight - Investing.com
Buy Rating for Vera Therapeutics Driven by Promising Phase III Results and Market Potential - TipRanks
BNP Paribas Financial Markets Purchases Shares of 24,374 Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics Holds 2025 Annual Stockholder Meeting - TipRanks
Dimensional Fund Advisors LP Trims Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
0.00%
0.54%
자본화:
|
볼륨(24시간):